LongevityNext discovery hub
Interpretive frameworks and evidence standards for aging science.
Source-reviewed intelligence
Directly related records lead this section.
Evidence reviewed
A claim-to-evidence framework separating exposure, target engagement, biomarker movement, safety and clinical benefit.
Boundary: Interpretive context does not establish that an intervention works.
Evidence reviewed
Maps inflammaging definitions, human measures, outcome associations, mechanisms and intervention limits.
Boundary: Inflammatory markers and their reduction are not validated proof of slower aging or longevity benefit.
Evidence reviewed
The aging Hallmarks are an influential research framework, not a complete causal theory, treatment checklist or validated endpoint set.
Boundary: Framework context does not validate an intervention, biomarker or clinical endpoint.
Source-reviewed intelligence
Additional directly related records follow the section-specific lead set.
Evidence reviewed
A role-based framework for reading trial endpoints, estimands, multiplicity, clinical meaning and surrogate claims.
Boundary: Endpoint labels alone do not establish confirmatory force or clinical importance.
Evidence reviewed
Separates DO-HEALTH's null primary clinical endpoint family from a later small post hoc DNA-methylation signal.
Boundary: Clock changes are not proof of slower clinical aging, healthspan or lifespan.
Evidence reviewed
Tracks TAME's proposed design, composite endpoint, funding, registration and launch status without treating plans as results.
Boundary: Design and status are not results; metformin is not established as an anti-aging treatment.
Evidence reviewed
Separates molecule-specific clinical outcomes from observational, mechanistic and direct longevity claims.
Boundary: Benefits in indicated high-risk populations do not establish direct slowing of aging or lifespan extension in generally healthy people.
Evidence reviewed
Research-stage DNA methylation age and pace-of-aging measures with bounded utility claims.
Boundary: Does not establish diagnosis, clinical utility or a definitive biological-age reading.
Evidence reviewed
A small randomized crossover mechanistic study in older adults with impaired glucose tolerance.
Boundary: Not clinical longevity-outcome, treatment, prevention or dosing evidence.
Evidence reviewed
Compares molecular, organ-level, functional and clinical aging measures by intended use, validation and limits.
Boundary: Age prediction, outcome association or intervention response does not establish a validated aging-rate or clinical surrogate.
Evidence reviewed
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
LN Pro preview